In Q3 FY2021 (ended September 30, 2020), Cogent Biosciences reported revenue of $312,000, a 69.4% decrease year-over-year. Net loss was $97.4 million, operating loss was $103.6 million, and diluted EPS was -$0.53. The company's financials reflect a pre-revenue biotech stage with significant R&D spending.
•Revenue fell 69.4% YoY to $312,000.
•Net loss widened 35.2% to $97.4 million.
•Operating loss increased 38.3% to $103.6 million.
•Diluted EPS was -$0.53, slightly worse YoY.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Cogent Biosciences, Inc., a clinical-stage biotechnology company focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
It also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations Including advanced cholangiocarcinoma. Its portfolio also includes CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications, and CGT6297, a Novel PI3Ka mutant-selective inhibitor.
It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. Its lead product candidate is bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor currently in Phase 3 trials. This drug is designed to target mutations within the KIT receptor tyrosine kinase, including the KIT D816V mutation that drives systemic mastocytosis, as well as other KIT exon 17 mutations found in patients with advanced gastrointestinal stromal tumors (GIST). The company also has other pipeline candidates: CGT4859, a reversible and selective FGFR2 inhibitor in Phase 1 for FGFR-mutated advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program for solid tumors with CNS involvement; and CGT6297, a PI3Ka mutant-selective inhibitor. Cogent Biosciences operates in the biotechnology industry within the healthcare sector.
Where is Cogent Biosciences (COGT) listed and what currency does it trade in?
Cogent Biosciences, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol COGT. The company trades in United States Dollars (USD), which is the standard currency for stocks listed on U.S. exchanges. As a Nasdaq-listed company, it is subject to the listing requirements and regulations of the Nasdaq exchange, providing investors with a regulated and transparent trading environment.
What sector and industry does Cogent Biosciences (COGT) belong to?
Cogent Biosciences operates in the healthcare sector, specifically within the biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative therapies for genetically defined diseases. Its primary area of expertise is precision medicine, targeting specific genetic mutations such as KIT, FGFR, ErbB2, and PI3Ka. The company's work is at the clinical stage, meaning its product candidates are undergoing human trials to assess safety and efficacy before potential regulatory approval and commercialization.
Where is Cogent Biosciences headquartered and what markets does it serve?
Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts, United States. The company primarily serves the U.S. market, as indicated by its country and region designation. Its clinical trials and research activities are likely conducted in the U.S., and it targets diseases prevalent in the American population. While the company may have global aspirations, its current operations and focus are centered in the United States, where it develops therapies for systemic mastocytosis, gastrointestinal stromal tumors, cholangiocarcinoma, and other solid tumors with specific genetic mutations.
What is the business model of Cogent Biosciences (COGT) and how does it generate revenue?
Cogent Biosciences is a clinical-stage biotechnology company, meaning it does not yet have approved products on the market and currently generates no revenue from product sales. Its business model revolves around research and development of precision therapies for genetically defined diseases. The company advances its drug candidates through preclinical and clinical trials, aiming to obtain regulatory approval from agencies like the FDA. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of its lead candidate, bezuclastinib. Revenue, if any, would come from collaboration agreements, licensing fees, or milestone payments until its drugs are approved and commercialized. The company's portfolio includes multiple programs targeting specific mutations in KIT, FGFR, ErbB2, and PI3Ka, which represent potential future revenue streams if successfully developed and marketed.